Cargando…
Combined epigenetic and metabolic treatments overcome differentiation blockade in acute myeloid leukemia
A hallmark of acute myeloid leukemia (AML) is the inability of self-renewing malignant cells to mature into a non-dividing terminally differentiated state. This differentiation block has been linked to dysregulation of multiple cellular processes, including transcriptional, chromatin, and metabolic...
Autores principales: | Zee, Barry M., Poels, Kamrine E., Yao, Cong-Hui, Kawabata, Kimihito C., Wu, Gongwei, Duy, Cihangir, Jacobus, William D., Senior, Elizabeth, Endress, Jennifer E., Jambhekar, Ashwini, Lovitch, Scott B., Ma, Jiexian, Dhall, Abhinav, Harris, Isaac S., Blanco, M. Andres, Sykes, David B., Licht, Jonathan D., Weinstock, David M., Melnick, Ari, Haigis, Marcia C., Michor, Franziska, Shi, Yang |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elsevier
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8192696/ https://www.ncbi.nlm.nih.gov/pubmed/34151238 http://dx.doi.org/10.1016/j.isci.2021.102651 |
Ejemplares similares
-
Comparison of TP53 Mutations in Myelodysplasia and Acute Leukemia Suggests Divergent Roles in Initiation and Progression
por: Jambhekar, Ashwini, et al.
Publicado: (2023) -
Intersection of Epigenetic and Metabolic Regulation of Histone Modifications in Acute Myeloid Leukemia
por: Dhall, Abhinav, et al.
Publicado: (2019) -
Identification of optimal dosing schedules of dacomitinib and osimertinib for a phase I/II trial in advanced EGFR-mutant non-small cell lung cancer
por: Poels, Kamrine E., et al.
Publicado: (2021) -
Author Correction: Identification of optimal dosing schedules of dacomitinib and osimertinib for a phase I/II trial in advanced EGFR-mutant non-small cell lung cancer
por: Poels, Kamrine E., et al.
Publicado: (2022) -
Principles, mechanisms and functions of entrainment in biological oscillators
por: Jiménez, Alba, et al.
Publicado: (2022)